Deals channel feed – Endpoints News

Deals channel feed

Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report

4 years ago

Hedge fund jumps in with Avoro activists in an attempt to derail Merck's $11B Acceleron buyout

4 years ago

'No excuse': ICER determines AstraZeneca's new moneymaker Soliris is vastly overpriced

4 years ago

Takeda, Wave Life Sciences revise their $230M R&D collaboration, dropping discovery work

4 years ago

Still reeling from PhII failure, Calithera beefs up its oncology portfolio with a little help from Takeda

4 years ago

A Bob Nelsen startup turns to Harvard to help sharpen its tech, inspiring first spinout

4 years ago

This midwestern CDMO just picked up 3 acquisitions in less than a week

4 years ago

A California biotech steps into the viral vector space with new site build of $75M

4 years ago

Bristol Myers wants to pull out of its Abraxane deal in China. BeiGene says no way

4 years ago

Charles River Laboratories has been on an acquisition spree. But Tuesday, it offloaded two assets

4 years ago

Drawn to the idea of turning B cells into 'protein factories,' Takeda jumps into a milestone-heavy, $900M pact

4 years ago

Intellia enters Editas’ turf with ocular CRISPR pact

4 years ago

GSK tangoes with private equity players to explore $54B sale of consumer unit instead of IPO — report

4 years ago

Inside the deal: As leaked details goosed its stock, Acceleron's CEO pumped Merck for more cash

4 years ago

Takeda enlists Poseida in $3.6B+ nonviral gene therapy deal, though data remain years away from human studies

4 years ago

Aceto keeps up spending spree with acquisition of Ireland's A&C

4 years ago

Supernus expands its portfolio of Parkinson's drugs with a $400M+ buyout

4 years ago

Flexion heads to the discount aisle for a $450M+ merger with Pacira

4 years ago

Lumen lands another DoD contract to treat Covid-related GI issues

4 years ago

As continent's vaccination rate sits below 5%, Moderna announces investment in mRNA manufacturing in Africa

4 years ago

Science 37 takes the SPAC shortcut to Nasdaq, landing a $235M windfall for its push on decentralized trials

4 years ago

Is the biotech boom starting to fade? The roaring ‘20s starts to look a little fatigued. Plus: Top 5 deals, IPOs, pacts of Q3

4 years ago

Troubled Voyager’s gene therapy relaunch gets a boost with $630M Pfizer deal

4 years ago

Has Selecta found a way around gene therapy's delivery problem? Takeda puts down $1B-plus to find out

4 years ago

First page Previous page 69 70 717273 74 75 Next page Last page